S-1: Profusa's Post-Merger S-1 Filing Details Share Resale, Financial Challenges

Profusa, Inc. filed an S-1 registration statement for the resale of up to 222 million shares by Ascent Partners Fund LLC, following its July 2025 business combination, while disclosing ongoing financial losses and going concern doubts.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corporation) completed its business combination on July 11, 2025.
• The company is a clinical-stage digital health and medical technology firm developing biointegrated sensors, including the Lumee Oxygen Platform and Lumee Glucose Platform.
• The Lumee Oxygen Platform, designed for tissue oxygen monitoring in conditions like peripheral artery disease and chronic wounds, has CE Mark approval in the EU and is undergoing U.S. clinical trials for FDA clearance.
• The Lumee Glucose Platform, a continuous glucose monitoring (CGM) system, is in clinical trials with proof-of-concept data showing a mean absolute relative difference (MARD) of approximately 11% and up to nine months of functionality post-injection, with no device-related serious adverse events reported.
• The filing registers up to 222,222,222 shares of common stock for resale by Ascent Partners Fund LLC, which were issued upon conversion of convertible promissory notes with an aggregate principal value of $22,222,222.
• Profusa will not receive any proceeds from the sale of these shares by the Selling Stockholder.
• The company has incurred significant net operating losses since inception, with a net loss of $5.1 million for the six months ended June 30, 2025, and $9.2 million for the year ended December 31, 2024.
• Management has substantial doubt about the company's ability to continue as a going concern, despite recent financing.
• A Committed Equity Facility with Ascent allows Profusa to sell up to $100 million of common stock over 36 months, with proceeds primarily for Bitcoin purchases, provided the cash balance exceeds $5 million.

Sentiment

Score: 3

Explanation: The company faces severe financial challenges, including substantial doubt about its ability to continue as a going concern, recurring losses, and Nasdaq delisting. While it has promising product development in biointegrated sensors and secured some financing, the overall financial health and operational risks are very high. The recent capital raises are critical but do not fully alleviate the going concern risk, and the bitcoin treasury strategy introduces additional volatility.

Positives

• Successful completion of the business combination on July 11, 2025, transitioning Profusa into a public company.
• Lumee Oxygen Platform has received CE Mark approval in the EU and is planned for commercialization in Europe in early 2026.
• Lumee Glucose Platform has generated promising proof-of-concept clinical data from 54 diabetes subjects, demonstrating potential for MARD of approximately 11% and up to nine months of functionality with zero device-related serious adverse events.
• The company's biosensor technology is designed to overcome the foreign body response, allowing for long-term functionality (up to 6-9 months) and ease of deployment via hypodermic needle.
• Strategic partnerships are being pursued in Asia Pacific markets through a joint venture with Tasly Holding Group Co. Ltd. or its affiliates.
• The company has secured a Committed Equity Facility of up to $100 million with Ascent Partners Fund LLC, providing a potential source of future capital.
• Strong intellectual property portfolio with 20 issued U.S. patents and 80 rest-of-world patents, expiring between March 2030 and January 2040.
• Management believes its technology platform can address a large addressable market, including over 500 million patients with diabetes and pre-diabetes in the U.S. and EU by end of 2025, and the growing telemedicine and health & wellness sectors.

Negatives

• The company has incurred significant net operating losses since inception, including $5.1 million for the six months ended June 30, 2025, and $9.2 million for the year ended December 31, 2024.
• Management has substantial doubt about the company's ability to continue as a going concern, with a working capital deficit of approximately $63.2 million as of June 30, 2025.
• The company will not receive any proceeds from the current S-1 registration statement, which is for the resale of shares by a selling stockholder.
• Lumee Glucose is an investigative product and not yet authorized for commercial sale in any jurisdiction.
• Commercialization efforts for Lumee Oxygen in Europe were hampered by COVID-19 pandemic restrictions.
• The company is in default on its PPP Loan 2 due to non-payment, and also on certain promissory notes to founders and insiders.
• The company's bitcoin treasury strategy exposes it to high volatility and counterparty risks, and changes in accounting treatment for bitcoin could increase financial result volatility.
• The company identified material weaknesses in internal control over financial reporting, including segregation of duties and review of valuations.
• The company's common stock was delisted from Nasdaq on December 20, 2024, and now trades on the Pink Markets (OTC Market).

Risks

• Substantial doubt about the ability to continue as a going concern, which may hinder future financing.
• Limited operating history and anticipated significant losses for several years.
• Highly competitive market with large, well-established companies.
• Risks due to international operations, including local preferences, payment cycles, currency fluctuations, and less intellectual property protection.
• Consumer confusion about product features and technology could lead to competitive product purchases or conflation of adverse events.
• Reliance on Lumee Oxygen Platform for nearly all commercial revenue until additional products receive regulatory approval.
• Dependence on third-party suppliers and outsourcing, leading to vulnerability to supply disruptions, suboptimal quality, noncompliance, and price fluctuations.
• No guarantee of FDA 510(k) clearance or PMA approval for products, which would adversely affect business growth.
• Failure to successfully complete pre-clinical studies or clinical trials for CGM systems.
• Products may cause or contribute to adverse medical events, failures, or malfunctions requiring FDA reporting, leading to sanctions or recalls.
• Quality problems could lead to recalls, safety alerts, and reputational harm.
• Changes to the regulatory landscape may impact marketing authorization.
• Failure to comply with laws, regulations, and contract requirements relating to healthcare reimbursement.
• Subject to complex and evolving U.S. and foreign laws regarding privacy, data protection, and security (e.g., HIPAA, CCPA, GDPR).
• Cybersecurity risks and cyber incidents could compromise confidential data or critical systems, leading to harm to customers, expenses, liability, and reputational damage.
• Claims of infringement or misappropriation of intellectual property rights of others, leading to shipping prohibitions, licensing requirements, or monetary damages.
• Inability to adequately protect intellectual property globally, allowing competitors to produce similar products.
• Involvement in expensive, time-consuming, and potentially unsuccessful lawsuits to protect patents.
• Claims challenging inventorship or ownership of patents and other intellectual property.
• Inadequate patent terms to protect competitive position.
• U.S. government funding for some patents grants the government an irrevocable, non-exclusive, royalty-free license, and potential "march-in" rights.
• Inability to successfully maintain effective internal control over financial reporting.
• Environmental, social, and corporate governance (ESG) regulations may complicate the supply chain and affect customer relationships.
• Uncertainty in domestic and global economic and political conditions, including inflation and military conflicts (Russia-Ukraine, Israel-Hamas).
• Changes in financial accounting standards or taxation rules.
• Manufacturing difficulties and disruptions at facilities could limit growth.
• Inability to attract and retain personnel and manage human capital while controlling labor costs.
• Export and import control laws and regulations could impair international competition or subject the company to liability.
• Limitations on the ability to use net operating losses (NOLs) to offset future taxable income due to Section 382 of the Internal Revenue Code.
• Customer or third-party complaints or negative publicity could harm reputation and brand.
• Addressable market size estimates may be smaller than anticipated.
• Adverse effects from disasters (e.g., earthquakes, wildfires, pandemics) on business continuity.
• Operating results may fluctuate significantly, making future results difficult to predict.
• Potential long-term complications from products not revealed by current clinical experience.
• Subject to federal, state, and foreign laws prohibiting kickbacks and false or fraudulent claims, with potential for substantial penalties.
• Delays or changes in regulatory approval standards.
• Product recalls even after FDA clearance or approval.
• Healthcare policy changes, including U.S. healthcare reform legislation, may adversely affect business.
• Increased costs and regulations as a public company.
• Risks associated with the bitcoin treasury strategy, including volatility, legal/regulatory uncertainty, counterparty risks, and potential reclassification as an investment company.
• No assurance of compliance with Nasdaq continued listing standards, potentially leading to delisting.
• Future sales or perception of future sales by shareholders could cause stock price decline.
• Grant and future exercise of registration rights may adversely affect market price.
• Issuance of additional shares under equity incentive plans or for acquisitions could dilute ownership.
• No current plans to pay cash dividends.
• Anti-takeover provisions in corporate documents.
• Exclusive forum provisions in the certificate of incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• Subject to securities litigation.

Future Outlook

Profusa plans to continue substantial investments in building its European and United States commercial infrastructure, enhancing existing products, and developing new ones. The company aims to launch Lumee Oxygen in Europe in early 2026 and in the U.S. in late 2026, subject to regulatory approval. Lumee Glucose is expected to begin its next validation study in the first half of 2026, with regulatory submission in early 2026, targeting a dual strategy of direct-to-hospital and direct-to-pharmacy sales. Profusa also intends to explore additional analytes and strategically engage in B2B data partnerships within the telemedicine and health and wellness sectors, leveraging its platform to provide real-time biochemistry data.

Management Comments

• Management believes this liquidity has not alleviated the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.
• Management believes this demonstrates that the non-invasive nature of a technology, even in the unlikely case it was of comparable accuracy to existing devices, has little bearing on marketability if other criteria are not met, such as competitive pricing, low production costs, user-friendliness and as well as pre-existing relationships with larger CGM players who can contribute to a plan to bring the product to market, all of which are areas where Profusa believes it has a winning advantage.
• Profusa believes that the combination of the potential advantages of this platform will enable it to generate both short-term revenue in the high-value clinical applications of wound care and diabetes management as noted above, but to also leverage core technology and develop and add to Profusa’s product portfolio to potentially tackle the management of other chronic conditions, while in the future creating the foundation for the technology enabled health care where the large volume of biomarker data aligned with up-to-the-minute actions and choices of the individual.
• Profusa believes that Lumees biosensor and artificial intelligence platform compares very attractively with some of the largest products in this market sector.
• Profusa believes its validated core technology can easily bridge the gap that exists in the current technology landscape for monitoring real time biochemistry.
• Profusa believes that, at scale, the data Profusa’s platform generates from its initial products will be a key enabler for the productivity and business models for both of these sectors to expand and reach more of their full potential.
• Profusa believes that its solution could benefit those in the type 2 and pre-diabetes populations to both potentially broaden the product reach beyond the currently available solutions, but also generate a broad set of clinical data across a large heterogeneous population to inform the clinical science behind diabetes care throughout the disease spectrum.
• Profusa believes that its ability to develop products to measure other analytes and expand our product portfolio is enhanced while maintaining the key value propositions of the platform.
• Profusa believes its technology could ultimately be that enabling data stream to these other high-growth healthcare sectors.

Industry Context

The medical device industry, particularly for oxygen monitoring and continuous glucose monitoring (CGM), is highly competitive and characterized by rapid technological change. Profusa operates in this environment, competing with large, established companies like Abbott Laboratories, Medtronic plc, and Roche Diabetes Care, which possess significant resources and market presence. The industry is also seeing a shift towards technology-enabled healthcare, including telemedicine and health and wellness coaching, which Profusa aims to capitalize on by providing real-time biochemical data. Regulatory changes, such as the 21st Century Cures Act and evolving FDA policies, continue to shape product development and market access. The broader digital assets industry, including bitcoin, introduces novel risks related to volatility, regulation, and counterparty exposure, which is relevant given Profusa's bitcoin treasury strategy.

Comparison to Industry Standards

• Lumee Oxygen Platform is designed to provide reliable tissue oxygen levels, competing with devices from Siemens Healthineers, Perimed AB, SenTec AG, Radiometer Medical, MESI, and ATYS Medical.
• Lumee Glucose aims to provide continuous glucose monitoring with a single injection for several months, offering an attractive alternative to current short-term needle-type CGMs (e.g., Dexcom G6, Abbott Freestyle Libre 2, Medtronic Guardian Connect, Senseonics Eversense E3) that require frequent sensor replacement.
• Profusa's glucose platform demonstrated a Mean Absolute Relative Difference (MARD) of approximately 11% in clinical studies, which is a key metric for CGM accuracy, comparable to or aiming to improve upon existing solutions.
• The company believes its low-cost manufacturing and user-friendly deployment via hypodermic needle offer advantages over more invasive or short-lived competitive products.
• Profusa's technology is positioned to bridge the gap between tailored clinical applications (high cost, burdensome user experience like current CGMs) and broad consumer-friendly solutions (limited clinical utility like health and wellness wearables).

Management Changes

Corporate Governance

Legal Proceedings

• Currently defending one litigation with a vendor, with estimated incremental legal costs of less than $0.1 million.
• Potential for product liability claims inherent in medical device design, manufacture, and marketing.
• Risk of claims of infringement or misappropriation of intellectual property rights from third parties.
• Risk of lawsuits to protect or enforce patents.
• Risk of claims that employees, consultants, or contractors wrongfully used or disclosed trade secrets.
• Potential for regulatory enforcement actions (e.g., warning letters, fines, product recalls) for non-compliance with FDA regulations or improper promotion.
• Subject to federal, state, and foreign laws prohibiting kickbacks and false or fraudulent claims, with potential for substantial penalties.
• Risk of being classified as an investment company under the 1940 Act if bitcoin is reclassified as a security and holdings exceed 40% of assets.
• Excise tax payable of $1,952,662 as of June 30, 2025, due to stock repurchases, with potential for additional interest and penalties for non-payment.

Related Party Transactions

• Investor Rights Agreement (IRA): Entered in May 2018 with certain preferred and common stockholders (including affiliates of directors/executive officers), providing registration rights, information rights, and right of first refusal. Terminated upon merger closing.
• Voting Agreement: Entered in May 2018 with certain preferred and common stockholders (including affiliates of directors/executive officers), agreeing to vote shares for election of directors and specified transactions. Terminated upon merger closing.
• Right of First Refusal and Co-Sale Agreement: Entered in May 2018 with certain preferred and common stockholders (including affiliates of directors/executive officers), giving Profusa a right of first refusal on certain security sales, and then preferred stockholders co-sale rights. Terminated upon merger closing.
• APAC Joint Venture Term Sheet: Entered in July 2020 (amended May 10, 2023) with Carbis Bay Limited, BC hSensor Limited, and Tasly (International) Healthcare Capital Company Limited (Investors). Profusa to form a JV, grant an exclusive license for Licensed Products in Asia Pacific, and receive JV ordinary shares worth $10 million. Tasly would then purchase 60% of JV shares from Profusa for $6 million.
• Tasly Convertible Debt: Short-term loan agreement with Tasly (International) Healthcare Investment & Development Company Limited (a shareholder of Profusa). Up to $1.6 million borrowed (final $0.02 million in Feb 2024). Bears 12% interest (24% default rate). Matured Dec 31, 2023, extended to March 31, 2024, now in default. Lender has option to convert to senior unsecured promissory notes or common stock at $1.92/share if APAC JV fails or debt not repaid. Fair value $2.5 million as of June 30, 2025.
• Equity Grants to Executive Officers and Directors: Stock options granted to executive officers and certain directors. Two KOLs received stock options for 10,000 and 30,000 shares, respectively.
• Severance Arrangements: Dr. Hwang's offer letter provides six months base salary plus pro-rata bonus and COBRA premiums upon termination without cause.
• Indemnification Agreements: New agreements with directors and executive officers for indemnification to the fullest extent by Delaware law.
• NorthView Founder Shares: Sponsor purchased 5,175,000 founder shares for $25,000 in April 2021 (adjusted to 4,743,750 shares after forfeiture and stock dividend). Subject to lock-up.
• NorthView Private Placement Warrants: Sponsor, I-Bankers Securities, Inc., and Dawson James Securities, Inc. purchased 7,347,500 warrants for $1.00 each ($7,347,500 total). Sponsor purchased 5,162,500. Not redeemable and exercisable for cash or cashless if held by initial purchasers/permitted transferees.
• NorthView Convertible Working Capital Promissory Note: Sponsor loaned up to $2.5 million (amended May 31, 2024), non-interest bearing, due at business combination or liquidation. Convertible into warrants at $1.00/warrant or common stock at $2.22/share at sponsor's election. Outstanding principal $1,919,796 (fair value $10,288,111) as of June 30, 2025. Repayment deferred to six months after closing.
• NorthView Administrative Services Agreement: Paid Sponsor $5,000/month for office space and services, terminated June 30, 2023. $50,000 still due to related party as of June 30, 2025.
• Advances from Profusa (to NorthView): Profusa advanced $1,299,040 to NorthView as of June 30, 2025, due upon demand or business combination completion.
• Business Combination Marketing Agreement: Company obligated to pay I-Bankers and Dawson James $2,000,000 cash fee upon business combination. $900,000 paid to I-Bankers, $600,000 to Dawson James, $500,000 deferred.
• Advisory Agreement (A.G.P.): Company to pay A.G.P. a 9.0% cash fee on convertible note offerings, payable at business combination close. Settlement agreement for $968,000 related to debt private placement, $550,000 paid at closing, $418,000 deferred until second tranche or Dec 31, 2025.
• Advisory Agreement (Benchmark Company LLC): Advisory fee of $750,000 for business combination, $500,000 in common stock (Tranche 1) and $250,000 in cash or stock (Tranche 2). Tranche 1 paid in shares.

Stakeholder Impact

• Shareholders: Significant dilution risk from future equity issuances (PIPE, ELOC, equity incentive plan, acquisitions). Market price volatility due to financial performance, bitcoin strategy, and delisting from Nasdaq. No cash dividends planned. Anti-takeover provisions may limit influence. Exclusive forum provisions may limit legal recourse.
• Employees: Future success depends on ability to attract and retain key personnel. Stock-based compensation is a component of remuneration.
• Customers: Potential for new and improved products (Lumee Oxygen, Lumee Glucose) to address critical health needs. Risks of product recalls, safety issues, or lack of regulatory approval could impact product availability and trust.
• Suppliers: Dependence on third-party suppliers creates vulnerability to disruptions, quality issues, and price fluctuations.
• Creditors: Company has substantial debt and is in default on some loans, raising concerns about repayment ability. Recent capital raises and future financing are critical for meeting obligations.
• Regulatory Bodies: Company is subject to extensive preand post-market regulation by FDA and foreign authorities, with risks of penalties for non-compliance.

Next Steps

• Continue to build European and United States commercial infrastructure.
• Enhance existing products and develop new ones.
• Continue discussions with potential partners in Asia.
• Initiate commercialization of Lumee Oxygen in Europe in early 2026.
• Continue U.S. study for Lumee Oxygen for FDA marketing authorization, targeting late 2026.
• Start the next validation study for Lumee Glucose in the first half of 2026.
• Submit for regulatory approval for Lumee Glucose in early 2026.
• Implement a dual commercialization strategy for Lumee Glucose (direct to hospital and direct to pharmacy sales).
• Seek to obtain additional 510(k) clearances or PMAs for new products or modifications.
• Address material weaknesses in internal control over financial reporting, including establishing reporting controls and segregation of duties.
• Finalize accounting conclusions on warrants issued to Ascent.
• Continue to monitor and potentially modify protective measures against cybersecurity threats.
• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03).
• Potentially acquire or invest in complementary businesses, products, and technologies.
• Seek additional equity or debt financing beyond current funding.
• Negotiate and execute definitive agreements for the APAC Joint Venture.
• Apply for forgiveness for PPP Loan 2.
• Repay or convert outstanding promissory notes to founders and insiders.
• Pay deferred Business Combination marketing fees.

Key Dates

Recommendation

Profusa is at a critical juncture, having recently completed its business combination and secured significant funding commitments. The company's core technology in biointegrated sensors for oxygen and glucose monitoring shows promising clinical data and addresses large, unmet medical needs. However, the company faces substantial financial risks, including recurring losses, a going concern warning, and Nasdaq delisting. The bitcoin treasury strategy introduces additional, significant volatility. While the long-term potential of its technology is notable, the immediate financial instability and execution risks warrant a cautious 'hold' stance. Investors should monitor progress on regulatory approvals, commercialization efforts, and financial stability, particularly the resolution of the going concern issue and the impact of the bitcoin strategy, before considering further investment.

Keywords

Profusa, biointegrated sensors, Lumee Oxygen Platform, Lumee Glucose Platform, continuous glucose monitoring, CGM, medical devices, digital health, SEC filing, S-1, Ascent Partners Fund LLC, convertible notes, PIPE transaction, going concern, FDA approval, CE Mark, clinical trials, intellectual property, healthcare technology, Nasdaq delisting, bitcoin treasury strategy